US FDA proposes another expedited pathway, but this time for 'limited' use
This article was originally published in Scrip
Executive Summary
The US FDA is moving forward with plans to create a new shortened regulatory pathway for drugs aimed at treating serious or life-threatening conditions for which there are unmet medical needs – permitting manufacturers to take a streamlined approach with shorter studies using smaller patient populations.